Paroxetine

Paroxetine Impurities

Paroxetine impurities include process-related compounds, synthetic intermediates, and degradation products that may arise during synthesis, formulation, or storage. As a selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression and anxiety disorders, impurity profiling is essential to ensure product safety, therapeutic efficacy, and regulatory compliance. All impurity compounds are structurally characterized and qualified under ICH guidelines for toxicological evaluation and analytical validation.

Paroxetine EP Impurities

Pharmacopeial and non-pharmacopeial Paroxetine impurity compounds are available in compliance with European Pharmacopoeia (EP) specifications. These standards support analytical method development, impurity profiling, and stability testing. EP traceable materials are supplied with validated analytical data including purity, structural confirmation, and spectral characterization.

Paroxetine Related Compounds

Structurally related compounds and synthetic analogs associated with Paroxetine are included for use in impurity identification, toxicological qualification, and regulatory submission. These materials are thoroughly characterized and conform to international standards. Related compounds are used in forced degradation studies, genotoxicity assessments, and impurity threshold evaluations.

Paroxetine Impurity Reference Standards

Paroxetine impurity reference standards are provided with validated analytical data including purity, NMR, and MS. These standards are used in pharmaceutical research, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request and are routinely re-tested to ensure consistency and reliability.